NATALY AGABIN: Open Payments
NPI 1083150072 · GROVETOWN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$549 in 29 payments from 11 companies in 2025. Trend: 2023 $894 · 2024 $661 · 2025 $549
Food & beverage: $549
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $180 |
| Abbott Laboratories | 6 | $93 |
| PFIZER INC. | 2 | $43 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Lilly USA, LLC | 2 | $39 |
| ABBVIE INC. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Phadia US Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
Products named: Wegovy, Kerendia, CAPLYTA, AIRSUPRA, PREVNAR 20, Ozempic, ELIQUIS, ZEPBOUND.
Industry payments across GA — which companies pay providers there.
